By Admera Health on May 28, 2020 3:13:32 PM
RxVision™: A Compendium of Knowledge-Part 3
The United States Food and Drug Administration (FDA): gene-drug interaction found on their tables and within drug labels
The Clinical Pharmacogenetics Implementation Consortium (CPIC): Level A and B gene-drug pairs and clinical practice guidelines
The Pharmacogenomics Knowledge Database (PharmGKB): Level 1 and 2 clinical annotations
The American Molecular Pathology Association: evidence-based expert consensus regarding alleles that should be included in clinical pharmacogenomic tests
IBM Micromedex: drug-drug, drug-food, drug-alcohol, and drug-lab interactions
The FDA Table of Pharmacogenomics Associations illustrates patient subgroups with specific genetic variants or genetic variant-inferred phenotypes that are likely to have altered drug metabolism, and in some instances, differential therapeutic effects, including differences in adverse event risks
The Table of Pharmacogenomic Biomarkers in Drug Labeling lists therapeutic products from the Drugs@FDA website with pharmacogenomic information in their drug labeling
From IBM Micromedex, Admera Health sources drug-drug, drug-food, drug-alcohol, and drug-lab interactions, as well as drug information including therapeutic class and mechanism of action.
RxVision™ allows providers to view Admera Health’s PGxOne™ Plus test results in an easy-to-use, dynamic format. This post serves as part-three in the RxVision™ blog series, that will touch upon the following topics:
RxVision™ is able to provide longer-term functionality for users with their PGx results—versus other static PGx reports
New medications can be checked against available PGx results for gene-drug interactions
RxVision™ combines drug-drug, drug-food, drug-alcohol, and drug-lab interactions from a medication knowledge-base commonly used in EHRs, along with the patient's pharmacogenomics test results in one central data hub. Thus, eliminating the need to check for drug-drug, drug-food, and drug-lab interactions separately
This Clinical Decision Support System (CDSS) platform provides physicians the capability to print and share the report with other providers who see the same patient, as well as the ability to refer to other providers, that the patient or physician recommends
RxVision™ can be used in preemptive PGx workflows in addition to reactive PGx workflows
How to Get Started with Admera Health:
To get started with Admera Health, click here to fill out the PGxOne™ Plus Test order contact form, or by visiting admerahealth.com/ordernow. You can also reach out via phone at 908-222-0533 or by sending an email to email@example.com.
Follow the steps below to setup your RxVision™ account and access the CDSS platform.
Admera’s PGxOne™ Plus is a pharmacogenomics test that provides insight for therapeutic decisions.
Over 50 genes | Over 200 variants
Ordering PGxOne™ Plus test sample collections supplies online is a quick and painless process.
About the Author(s):
Dr. Shalis Ammons is the Product Manager for Admera Health's PGxOneTM Plus test. She has earned her doctoral degree in Genetics, Cell Biology and Anatomy at the University of Nebraska Medical Center. After graduation, she transitioned into the commercial side of the life science industry and has been working in marketing for about three years. She can be contacted at firstname.lastname@example.org or 908-222-0533 ext. 3880.
Becky Winslow is the Senior Clinical Specialist for the PGxOneTM Plus test in the medical affairs department of Admera Health. She earned her Bachelor of Science in Biology and her Doctorate of Clinical Pharmacy at Campbell University School of Pharmacy. Additionally, she earned her Community Based Pharmacogenomics Program Certificate and her certification to teach pharmacogenomics from the University of Pittsburgh School of Pharmacy. Becky has more than 20 years of clinical pharmacotherapy and pharmacy business operations experience, which includes six years of experience as a pharmacogenomics medical science liaison and clinical implementation specialist. She can be contacted at email@example.com or 908-222-0533 ext. 3933.